Proactive Investors - Run By Investors For Investors

Tissue Regenix building its capabilities for future sustainable delivery

Steve Couldwell, chief executive of Tissue Regenix Group PLC (LON:TRX), caught up with Proactive's Andrew Scott to discuss the group's interim 2018 results.

In the six months to the end of June they inked distribution agreements with Arthrex and ARMS Medical of the US and Pennine Healthcare here in the UK.

Another milestone was British regulatory sign-off for the BioRinse portfolio, while manufacturing of DermaPure, the company’s wound care product, has been successfully transferred to the CellRight facility in Texas  ahead of schedule.

Couldwell says they've identified a number of potential new commercial opportunities they are “actively pursuing”.

View full TRX profile View Profile

Tissue Regenix Group PLC Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use